Haitao Wang
Tianjin Medical University Second Hospital · Tianjin Medical Unversity Second Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
18
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
1 more share only the name and are not shown
Trial papers
3684
PubMed author-name match
Trials
Studies that name Haitao Wang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:19 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07917351 · AI-Assisted Whole-Course Management for Medication Safety and Healthcare Burden in Advanced Solid Tumors: A Prospective Controlled StudyTianjin Medical University Second Hospital · recruiting · Digital Health, Artificial Intelligence (AI) · principal investigator
- N/ANCT07906301 · Organoid Drug Sensitivity-Guided Therapy for Refractory TumorsTianjin Medical University Second Hospital · recruiting · Refractory Tumors, Organoid · study chair
- Ph2NCT07712029 · Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-PositiveTianjin Medical University Second Hospital · recruiting · Advanced Refractory Solid Tumors, EGFR Gene Overexpression · principal investigator
- Ph2NCT07179783 · Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)Tianjin Medical University Second Hospital · recruiting · Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant, Prostate Adenocarcinoma With Neuroendocrine Differentiation · study chair
- Ph2NCT07170293 · Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid TumorsTianjin Medical University Second Hospital · recruiting · Solid Cancers · principal investigator
- Ph2NCT06739395 · Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionTianjin Medical University Second Hospital · recruiting · Solid Tumor, Precision Medicine · principal investigator
- N/ANCT06030869 · MyCustom:Prospective Master Protocol Trial on Precision Medicine Treatment for Refractory Solid TumorsTianjin Medical University Second Hospital · unknown · Refractory Solid Tumors, Next Generation Sequencing · principal investigator
- Ph2NCT06022289 · Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid TumorsTianjin Medical University Second Hospital · unknown · Solid Tumor, FGF Receptor Gene Mutation, FGF Amplification · principal investigator
- N/ANCT06022276 · Nimotuzumab for EGFR-amplified Advanced Pan Solid TumorsTianjin Medical University Second Hospital · unknown · Solid Tumor, EGFR Amplification · principal investigator
- N/ANCT06009835 · DOTr/DOTa Algorithm Guidance for Refractory Solid TumorsTianjin Medical University Second Hospital · unknown · Solid Tumor, Individuation · principal investigator
- Ph2NCT04995016 · Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell CarcinomaTianjin Medical University Second Hospital · unknown · Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma · study director
- Ph2NCT04958473 · A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell CancerTianjin Medical University Second Hospital · unknown · Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma · study director
- Ph1/Ph2NCT04659785 · A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）Tianjin Medical University Second Hospital · unknown · Small Cell Lung Cancer Extensive Stage · principal investigator
- Ph2NCT04179656 · The Basket Study of Pyrotinib Maleate for HER2-Postive Solid TumorTianjin Medical University Second Hospital · unknown · Solid Tumor, HER2 Gene Mutation, HER-2 Gene Amplification · principal investigator
- N/ANCT03929653 · Personalized Therapy of Molecular Tumor Board Participation With the Guidance of Next Generation SequencingTianjin Medical University Second Hospital · unknown · Solid Tumor, Adult · principal investigator
- N/ANCT03927599 · Advanced Refractory Solid Tumors With TP53 Mutations Register StudyTianjin Medical University Second Hospital · unknown · Solid Tumor, Adult · principal investigator
- N/ANCT03786848 · Personalized Mini-PDX for Metastatic CRPCTianjin Medical University Second Hospital · unknown · Prostate Cancer · principal investigator
- Ph1NCT03645200 · Treatment of Carrying TP53 Harmful MutationsTianjin Medical University Second Hospital · unknown · Advanced Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:19 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:19 UTC. The ranking covers the 200 most relevant of 3684 PubMed records, and a shared surname and initials can bring in a namesake. All 3684 on PubMed
- 152 citationsRCR 43.1
- Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.N Engl J Med · 2026103 citationsRCR 51.5
- Clinical investigation on nebulized human umbilical cord MSC-derived extracellular vesicles for pulmonary fibrosis treatment.Signal Transduct Target Ther · 202579 citationsRCR 22.2
- Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial.Cancer Commun (Lond) · 202463 citationsRCR 7.9
- Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction.Alzheimers Dement · 202563 citationsRCR 17.0
- 60 citationsRCR 18.7
- Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke.N Engl J Med · 202556 citationsRCR 16.3
- 48 citationsRCR 17.1
- 47 citationsRCR 7.3
- Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers: Results From the OCEAN(a)-DOSE Trial.JAMA Cardiol · 202544 citationsRCR 11.3